Shallow whole-genome sequencing genomic instability score across endometrial cancer subtypes.

e17632 Background: Genomic instability (GI) is a hallmark of cancer. In endometrial cancer (EC) the TCGA molecular classification is prognostic. GI scores (GIS) are widely studied and clinically validated in high grade serous ovarian cancer (HGSOC). The distribution and biological significance of GIS scores in EC remain unclear. We aimed to characterize and explore GI across EC subtypes using shallow whole-genome sequencing. Methods: Up to 96 prospective FFPE EC samples were included, mainly presenting endometrioid (72 %), and serous histologies (14.5 %). The remaining 13.5 % include clear cell and mixed histologies. Stage was categorized as follows: I/II (66.7 %) and III/IV (33.3 %). Cases without primary surgery were excluded from survival analysis. Molecular classification frequencies were CNH (22.9%), CNL (39.6 %), MSI-H (30.2 %) and POLE (7.3 %). Libraries were constructed using HyperPlus kit (Roche diagnostics) and sequenced in a NextSeq 2000 (2x100 paired-end) (Illumina) to achieve a 0.5x coverage. Copy-number (CN) calling and GIS were obtained using QDNA and ShallowHRD. Data were further compared with our own GIS in 60 HGSOC (Romero, I ASCO 2025). All the analyses were performed in Python v3.8 and R v.4.3.11. Results: Basic clinical characteristics and sequencing performance parameters are detailed in table 1. In EC, GIS decreasingly ranged from CNH, CNL, MSI-H to POLE (Table 1) showed statistically significant differences between CNH and the rest of molecular subtypes (p=0.00027). Higher GIS also correlated with serous histology (p=4.6*10 -5 ) and worse PFS (P=0.0062). GIS showed consistently lower values in EC than HGSOC (table 1, p<2*10 -16 ). Among CNH group, highest GIS values (q4) had worse PFS and OS (both p=0.05). CN at chromosomic level were evaluated: amplifications in chromosome 1 and 10 were enriched in MSI-H (p=0.0002) and CNL (p=0.0277) groups respectively. Chromosome 1 CN was correlated with endometrioid histology (p=0.007851). Conclusions: Shallow whole-genome sequencing is a valuable approach to characterize GI across EC populations. However, additional GI parameters should be explored to better understand the nature and possible biological sources of GI in EC. Main clinical and sequencing performance parameters of the EC series. Parameter Median [range] Age at diagnosis (years) 62 [40-89] Progression-Free Survival (PFS, months) 17.33 [0-158.367] Overall Survival (PFS, months) 19.55 [0-186.667] Follow-up (months) 19.55 [0-186.667] Total reads 21740865.5 [1169173-347460678] Whole-genome coverage 0.642 [0.024-10.366] Targeted-sequence coverage 2.111 [1.814-208.054] Genome covered (%) 30.519 [0.012-89.132] Genomic Instability Score (GIS) CNH 5 [0-42] CNL 0 [0-14] MSI-H 0 [0-5] POLE 0 [0-2] CE-GIS 1 [0-42] HGSOC-GIS 20 [1-43]

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2026-05-28
DOI
https://doi.org/10.1200/jco.2026.44.16_suppl.e17632
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Shallow whole-genome sequencing genomic instability score across endometrial cancer subtypes.

Raquel López-Reig, Ignacio Romero, Antonio Fernández Serra, Jessica Aliaga et al.
Journal of Clinical Oncology
Cancer Genomics and Diagnostics
article

Shallow whole-genome sequencing genomic instability score across endometrial cancer subtypes.

Raquel López-Reig, Ignacio Romero, Antonio Fernández Serra, Jessica Aliaga, Jose Antonio Lopez Guerrero, Cristina Diaz Sierra, Tatiana Ugalde Catarinella
article en

Abstract

e17632 Background: Genomic instability (GI) is a hallmark of cancer. In endometrial cancer (EC) the TCGA molecular classification is prognostic. GI scores (GIS) are widely studied and clinically validated in high grade serous ovarian cancer (HGSOC). The distribution and biological significance of GIS scores in EC remain unclear. We aimed to characterize and explore GI across EC subtypes using shallow whole-genome sequencing. Methods: Up to 96 prospective FFPE EC samples were included, mainly presenting endometrioid (72 %), and serous histologies (14.5 %). The remaining 13.5 % include clear cell and mixed histologies. Stage was categorized as follows: I/II (66.7 %) and III/IV (33.3 %). Cases without primary surgery were excluded from survival analysis. Molecular classification frequencies were CNH (22.9%), CNL (39.6 %), MSI-H (30.2 %) and POLE (7.3 %). Libraries were constructed using HyperPlus kit (Roche diagnostics) and sequenced in a NextSeq 2000 (2x100 paired-end) (Illumina) to achieve a 0.5x coverage. Copy-number (CN) calling and GIS were obtained using QDNA and ShallowHRD. Data were further compared with our own GIS in 60 HGSOC (Romero, I ASCO 2025). All the analyses were performed in Python v3.8 and R v.4.3.11. Results: Basic clinical characteristics and sequencing performance parameters are detailed in table 1. In EC, GIS decreasingly ranged from CNH, CNL, MSI-H to POLE (Table 1) showed statistically significant differences between CNH and the rest of molecular subtypes (p=0.00027). Higher GIS also correlated with serous histology (p=4.6*10 -5 ) and worse PFS (P=0.0062). GIS showed consistently lower values in EC than HGSOC (table 1, p<2*10 -16 ). Among CNH group, highest GIS values (q4) had worse PFS and OS (both p=0.05). CN at chromosomic level were evaluated: amplifications in chromosome 1 and 10 were enriched in MSI-H (p=0.0002) and CNL (p=0.0277) groups respectively. Chromosome 1 CN was correlated with endometrioid histology (p=0.007851). Conclusions: Shallow whole-genome sequencing is a valuable approach to characterize GI across EC populations. However, additional GI parameters should be explored to better understand the nature and possible biological sources of GI in EC. Main clinical and sequencing performance parameters of the EC series. Parameter Median [range] Age at diagnosis (years) 62 [40-89] Progression-Free Survival (PFS, months) 17.33 [0-158.367] Overall Survival (PFS, months) 19.55 [0-186.667] Follow-up (months) 19.55 [0-186.667] Total reads 21740865.5 [1169173-347460678] Whole-genome coverage 0.642 [0.024-10.366] Targeted-sequence coverage 2.111 [1.814-208.054] Genome covered (%) 30.519 [0.012-89.132] Genomic Instability Score (GIS) CNH 5 [0-42] CNL 0 [0-14] MSI-H 0 [0-5] POLE 0 [0-2] CE-GIS 1 [0-42] HGSOC-GIS 20 [1-43]

Journal of Clinical OncologyVol. 44(16_suppl)
Fundación Instituto Valenciano de Oncología (ES), Spanish Ovarian Cancer Research Group (ES)
Generalitat Valenciana
Openalex Percentile: Top 7%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.